NCT06324604View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Healthy VolunteersCeliac DiseaseType 1 Diabetes
Interventions
DRUG

Placebo

Placebo

DRUG

MTX-101

MTX-101 (bispecific CD8 Treg modulator)

Trial Locations (4)

3050

RECRUITING

The Royal Melbourne Hospital, Melbourne

4006

COMPLETED

Nucleus Network Brisbane, Herston

4066

ACTIVE_NOT_RECRUITING

Wesley Research Institute, Auchenflower

Unknown

RECRUITING

Eastern Health; Box Hill Hospital, Box Hill

All Listed Sponsors
lead

Mozart Therapeutics Australia Pty Ltd

INDUSTRY